Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?
PSMA-directed radioligand therapy) early in the disease course? The therapeutic armamentarium of mCRPC has witnessed rapid evolution over the recent years, with a gamut of newly approved and "on-trial under clinical evaluation" therapies added to the traditional therapies including the cytotoxic che...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 47; no. 8; pp. 1793 - 1798 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144800947&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 144800947 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Jul2020 vid: 47 iid: 8 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 144800947 10.1007/s00259-019-04616-w 144800947 ppf: 1793 ppct: 5 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course? aug: au: Basu, Sandip Parghane, Rahul V. Suman, Sonam Joshi, Amit Prabhash, Kumar Bakshi, Ganesh Banerjee, Sharmila affil: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India sug: ab: PSMA-directed radioligand therapy) early in the disease course? The therapeutic armamentarium of mCRPC has witnessed rapid evolution over the recent years, with a gamut of newly approved and "on-trial under clinical evaluation" therapies added to the traditional therapies including the cytotoxic chemotherapy (taxanes) and immunotherapy (Sipuleucel-T) [[1]]. We have to mention here that [ SP 177 sp Lu]Lu-PSMA therapy, and also [ SP 68 sp Ga]Ga/[ SP 18 sp F]F-PSMA PET-CT imaging, though being now frequently adopted in advanced centres with such facilities, are still considered experimental in many of the European countries, the USA and other countries worldwide. Dual-tracer PET-CT in characterizing tumour biology of mCRPC: can this be employed for treatm... The concept of dual/multi-tracer PET-CT in studying and characterizing tumor biology can be considered an important development of recent years that has scientifically augmented the practice of precision oncology. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|